Compare DKS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DKS | BBIO |
|---|---|---|
| Founded | 1948 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 15.3B |
| IPO Year | 2002 | 2019 |
| Metric | DKS | BBIO |
|---|---|---|
| Price | $196.07 | $71.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 24 |
| Target Price | ★ $241.50 | $83.00 |
| AVG Volume (30 Days) | 1.0M | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 15.35 | N/A |
| EPS | ★ 8.66 | N/A |
| Revenue | ★ $13,442,849,000.00 | $502,076,000.00 |
| Revenue This Year | $30.99 | $88.86 |
| Revenue Next Year | $26.26 | $74.11 |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | 3.53 | ★ 126.26 |
| 52 Week Low | $166.37 | $28.33 |
| 52 Week High | $237.31 | $84.94 |
| Indicator | DKS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 52.30 |
| Support Level | $168.88 | $70.65 |
| Resistance Level | $233.78 | $79.56 |
| Average True Range (ATR) | 6.89 | 3.33 |
| MACD | -1.19 | 0.67 |
| Stochastic Oscillator | 20.60 | 65.78 |
Dick's Sporting Goods is a retailer that offers sports and outdoor apparel, footwear, and equipment online and in physical stores. The company's legacy business includes more than 700 stores under its own name, more than 110 Golf Galaxy golf specialty stores, and about 50 outlet stores. In September 2025, Dick's acquired multinational retailer Foot Locker. With this move, Dick's added about 2,600 stores under the Foot Locker, Kids Foot Locker, Champs Sports, atmos, and WSS nameplates in North America, the Asia-Pacific, and EMEA—Europe, the Middle East, and Africa. Based in the Pittsburgh area, Dick's was founded in 1948 by the father of current executive chair and controlling shareholder Edward Stack.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.